Articles tagged "Calcineurin"

2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
A. Rizvi¹, M. Kueht², S. Hussain³, J. Fair², R. Ramirez⁴, A. Gamilla-Crudo⁵, M. Mujtaba⁵
¹Internal Medicine, Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX, ²Surgery, University of Texas Medical Branch, Galveston, TX, ³University of Texas Medical Branch, Houston, TX, ⁴Surgery, University of Texas Medical Branch at Galveston, Galveston, TX, ⁵University of Texas Medical Branch, Galveston, TX
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
2022 American Transplant Congress
Impact of Belatacept Conversion on Renal Function and Donor Specific Antibodies in Renal Transplant Recipients
E. R. Brown, K. Cunningham, K. Paplaczyk, C. Dagostino, C. Kane, A. Shetty
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although associated with nephrotoxicity, calcineurin inhibitors (CNI) have historically been the cornerstone of immunosuppression. Belatacept, a co-stimulation blocker, is FDA-approved for de novo use…
2022 American Transplant Congress
Tacrolimus Induces Dedifferentiation of Pancreatic Beta Cells by Inhibition of Calcineurin/NFATc2 and Islet Cell Differentiation Genes
C. M. Darden¹, S. Vasu², J. Mattke³, Y. Liu², B. Naziruddin⁴, M. C. Lawrence²
¹Baylor University, Dallas, TX, ²Baylor University Medical Center, Dallas, TX, ³Baylor University, Waco, TX, ⁴Baylor University Medical Ctr, Dallas, TX
*Purpose: Tacrolimus (FK506) is a potent immunosuppressant widely used for solid organ transplantation to prevent lymphokine gene expression by inhibiting calcineurin (CN) and its downstream…
2022 American Transplant Congress
Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient
H. Sasaki, H. Harada, D. Takamoto, Y. Takada, S. Harada, H. Tanaka
Sapporo City General Hospital, Sapporo, Japan
*Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…
2022 American Transplant Congress
Post Transplant Virologic Outcomes in DCD Kidney Transplant Recipients Treated with Thymoglobulin Induction Immunosuppression and Maintenance Belatacept vs Calcineurin Inhibitor Therapy
T. Engebretsen¹, M. Kueht¹, A. Lea², M. Mujtaba³
¹Abdominal Transplant Surgery, University of Texas Medical Branch, Galveston, TX, ²Infectious Disease, University of Texas Medical Branch, Galveston, TX, ³Nephrology, University of Texas Medical Branch, Galveston, TX
*Purpose: Belatacept is an inhibitor of the T-Cell costimulatory pathway that can be used in recipients of Donation after Circulatory Death (DCD) where the intended…
2022 American Transplant Congress
Pediatric Liver Transplant Factors That Influence Tacrolimus Absorption
M. Chandran¹, D. Yoeli¹, A. Sater², F. Karrer¹, M. Adams¹
¹Children's Hospital Colorado, Aurora, CO, ²University of Colorado, Aurora, CO
*Purpose: The aim of this study was to investigate the association between various pediatric recipient characteristics at time of liver transplant and FK506 absorption 6…
2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
W. Asch¹, K. Belfield², V. Do², E. Cohen¹
¹Yale University, New Haven, CT, ²Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…
2021 American Transplant Congress
Cyp3a5 Extensive Metabolizer Phenotype May be Associated with an Increase in Class 2 Donor Specific Antibodies and Antibody-Mediated Rejection
S. Mirza¹, N. Wilson², J. Van Zyl², P. Nguyen², T. Sam², S. Hall², M. Askar², R. Patel²
¹Texas Tech Univeristy Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, ²Baylor University Medical Center at Dallas, Dallas, TX
*Purpose: Tacrolimus (TAC) metabolism is highly dependent on CYP3A5, yet there is limited data on the effect of CYP3A5 genetic polymorphisms in heart transplant recipients…
2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
2021 American Transplant Congress
Relationship Between Tacrolimus Blood Levels and Covid-19 Pandemic in Kidney Transplant Recipients
T. Inoue¹, K. Unagami,², A. Ishiwatari³, T. Kanzawa³, T. Shimizu³, K. Omoto³, M. Inui³, T. Suzuki¹, H. Ishida⁴, K. Tanabe³
¹Department of Nephrology, Kameda Medical Center, Chiba Kamogawa, Japan, ²Department of Organ Transplant Medicine, Tokyo Women’s Medical University, Tokyo, Japan, ³Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Department of Organ transplant medicine, Tokyo Women’s Medical University, Tokyo, Japan
*Purpose: The novel coronavirus 2019 infection (COVID-19) caused a pandemic, prompting Tokyo, Japan, to restrict on the free movement of people in March 2020. Kidney…